Business
Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium
Studies highlight findings regarding the potential use of (Z)-endoxifen to advance breast cancer treatment and risk reductionSEATTLE, Dec. 15, 2025
About this update from Atossa Therapeutics, Inc.
[{"type":"text","content":"Studies highlight findings regarding the potential use of (Z)-endoxifen to advance breast cancer treatment and risk reductionSEATTLE, Dec. 15, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (\"Atossa\" or the \"Company\"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of high unmet need, presented four clinical trial updates on (Z)-endoxifen at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025, in San Antonio, TX.\n \n \n \n \n \n \n \n\"Clinical trial updates and data presented at SABCS 2025 reinforce our focus on the therapeutic value of (Z)-endoxifen across the breast care continuum,\" said Steven Quay, M.D., Ph.D., Atossa Therapeutics' President and Chief Executive Officer. \"With support from our growing body of clinical evidence, we continue to advance our high value clinical programs. Following our more streamlined pathway for our Phase 2 EVANGELINE study, we expect continued enrollment and data generation for neoadjuvant ER+/HER2- breast cancer. Finally, we are committed to advancing a low-dose treatment strategy designed to reduce mammographic breast density. High mammographic breast density has been associated with a higher risk of developing future breast cancer.\"Presentation Highlights:Initial results from RECAST DCIS: Multicenter platform trial testing active surveillance and novel endocrine therapy agents for DCIS managementClinical significanceEarly RECAST findings suggest that short-term endocrine therapy combined with MRI response assessment may identify patients with low-risk DCIS who can avoid surgery and pursue active surveillance, offering a potential pathway to reduce overtreatment while personalizing careKey takeaways RECAST is testing whether short-term endocrine therapy plus MRI response can identify appropriate DCIS patients for long-term active surveillance while avoiding surgeryEarly results show excellent tolerability and steady enrollment, with many patients electing to continue active surveillance, suggesting feasibility of this patient-centered \"window of opportunity\" approachFuture work focuses on integrating imaging and molecular biomarkers to refine prediction of progression risk, guide personalized care pathways, improve patient experience and quality of life, and assess long-term outcomes includ...